In a landmark move that signals a paradigm shift in how chronic cardiovascular conditions are managed, Vivos Therapeutics, Inc. and South Palm Cardiovascular Associates LLC (SPCVA) have announced the signing of definitive collaboration and operating agreements. This partnership aims to establish a state-of-the-art regional Sleep & Airway Medicine Center in Palm Beach County, Florida, effectively integrating specialized sleep apnea care directly into the cardiovascular patient journey.
The collaboration centers on the formation of AIM Florida LLC, a physician-aligned management services organization (MSO) designed to streamline the diagnosis and treatment of obstructive sleep apnea (OSA). Under the proposed structure, Vivos Therapeutics is expected to hold a 75% majority interest in the venture, pending final regulatory compliance and approvals. This initiative represents more than just a new clinic; it is a strategic attempt to solve the long-standing clinical challenge of bridging the gap between heart health and airway obstruction.
Main Facts: The Anatomy of a Strategic Partnership
The agreement establishes a framework for a high-volume clinical model capable of addressing the needs of a patient base that is often overlooked in traditional silos. SPCVA, a prominent, physician-owned cardiology practice in South Florida, maintains a robust network with approximately 30,000 active patients. By embedding sleep medicine within their existing cardiovascular ecosystem, the partners intend to capture and treat undiagnosed cases of OSA—a condition that has long been identified as a significant comorbidity for hypertension, heart failure, and atrial fibrillation.
The operational core of this partnership is the establishment of a dedicated regional facility. Currently, both parties are in the final stages of evaluating site locations and finalizing lease negotiations in Palm Beach County. Once the site is secured, the project will move into a phase of rigorous build-out, facility licensing, and clinical staffing. If the current timeline holds, the center is expected to open its doors to patients in the first quarter of 2027.
The projected throughput for the facility is significant. The operational blueprint calls for a fully staffed team capable of managing approximately 250 patients per month. The model is intentionally scalable; as patient demand within the SPCVA network—and potentially beyond—grows, the infrastructure is designed to accommodate additional clinical teams to prevent bottlenecks.
Chronology: From Concept to Clinical Implementation
The journey toward this partnership began with the clinical observation that traditional referral pathways for sleep medicine were failing many cardiovascular patients. The following timeline outlines the progression of this strategic development:
- Initial Discovery: Leadership at SPCVA identified a significant clinical gap regarding patient access to timely sleep testing and effective, compliant treatment for OSA.
- Engagement Phase: Vivos Therapeutics introduced their proprietary, FDA-cleared technology suite to the SPCVA clinical leadership, demonstrating how integrated testing could fit into a cardiology workflow.
- Formalization: Both entities entered into negotiations, resulting in the signing of definitive collaboration and operating agreements.
- Establishment of AIM Florida: The creation of the MSO entity (AIM Florida LLC) serves as the operational vehicle for the expansion, with Vivos outlining its plan to hold a 75% majority interest.
- Site Selection (Ongoing): The current phase involves selecting a prime location in Palm Beach County that maximizes accessibility for the SPCVA patient population.
- Projected Launch (Q1 2027): Anticipated commencement of operations, including diagnostic testing, medical evaluation, and the rollout of multi-modal treatment plans.
Supporting Data: The Clinical Imperative for Sleep-Cardio Integration
The medical community has increasingly recognized that the "watch-and-wait" approach to mild-to-moderate OSA is insufficient, particularly for those with underlying heart conditions. For the 30,000 patients served by SPCVA, the risk of undiagnosed sleep-disordered breathing is not merely a quality-of-life issue; it is a potential driver of cardiac events.
The Diagnostic and Treatment Spectrum
The new center will not rely on a "one-size-fits-all" approach. Instead, it will offer a comprehensive array of diagnostic and therapeutic modalities. By bringing these under one roof, the center aims to eliminate the "patient attrition" that often occurs when a cardiologist refers a patient to an external sleep lab, only for the patient to never schedule the appointment.
The treatment modalities planned for the center include:
- Positive Airway Pressure (PAP) Therapy: The gold standard for many, provided with enhanced clinical support to ensure patient compliance.
- FDA-Cleared Oral Appliances: Designed for patients who are intolerant to PAP therapy or who have specific anatomical needs.
- Advanced Laser Therapy: A minimally invasive intervention aimed at tissue remodeling in the airway.
- Myofunctional Therapy: Targeted exercises that strengthen the muscles of the tongue and throat, often used in conjunction with other treatments to improve long-term outcomes.
By offering these options in a single coordinated model, the organizations aim to reduce patient confusion, which is historically a leading cause of non-adherence in sleep medicine.
Official Responses: Aligning Vision and Technology
The leadership teams from both Vivos and SPCVA view this as a transformative milestone in medical practice management.
Dr. Andres Ruiz, Leading Cardiologist at SPCVA:
"As cardiologists caring for tens of thousands of chronically ill patients throughout South Florida, we see the impact of obstructive sleep apnea every day," says Dr. Ruiz. He emphasizes the limitations of the current landscape: "We have witnessed the full spectrum—from patients with mild disease who were historically managed with a watch-and-wait approach, to those with severe OSA who struggled to achieve consistent compliance with traditional therapies."
For Dr. Ruiz, the partnership is about efficacy. "When Vivos introduced us to their FDA-cleared approach to OSA testing and treatment, we recognized an important opportunity to address this condition more directly and effectively. We believe that identifying and treating OSA can play a meaningful role in improving our patients’ overall health and outcomes."
R. Kirk Huntsman, Chairman and CEO of Vivos Therapeutics:
Huntsman views this agreement as a proof-of-concept for a broader strategy. "The execution of these definitive agreements is an important milestone in our strategy to partner directly with larger medical specialty groups and support their patients’ sleep and airway needs," he stated.
Huntsman highlighted the scalability of the model, noting that the combination of "SPCVA’s trusted physician relationships with Vivos’ technology and operating experience" allows for a capital-efficient expansion. By essentially "plugging" a sleep clinic into an existing, high-trust specialty practice, Vivos is effectively shortening the time to care and increasing the likelihood that patients will actually follow through on their treatment plans.
Implications: The Future of Integrated Care
The establishment of the Palm Beach County center carries significant implications for both the business of medicine and patient outcomes.
Implications for Patient Outcomes
The primary benefit is the reduction of fragmented care. When a cardiologist manages a patient’s heart health but is unaware of the severity of their sleep apnea, the treatment plan is inherently incomplete. By centralizing these services, the new center ensures that the sleep data informs the cardiology care plan. This integration can lead to better management of hypertension, reduced instances of nocturnal cardiac arrhythmias, and potentially lower rates of heart failure exacerbation.
Implications for the Healthcare Market
This partnership serves as a blueprint for the "Specialty-Integrated Sleep Model." As the healthcare industry moves toward value-based care, providers are under increasing pressure to demonstrate that their interventions lead to better long-term health outcomes at a lower total cost. By creating an MSO like AIM Florida, Vivos is positioning itself as a partner in value-based delivery. If successful, this model could be replicated in other high-population areas, allowing Vivos to scale its technology rapidly by leveraging the patient volumes of large, established specialty practices rather than relying solely on individual dental or sleep clinic referrals.
Addressing Compliance and Attrition
One of the most persistent issues in sleep medicine is the high rate of patient drop-off after an initial diagnosis. By managing the patient within the same ecosystem where they receive their cardiac care, the facility can leverage the established patient-doctor trust. When a cardiologist explains the link between a patient’s irregular heartbeat and their nighttime breathing, the patient is statistically more likely to adhere to the prescribed OSA treatment.
As the project moves toward its Q1 2027 launch, the healthcare industry will be watching closely. If the Vivos-SPCVA model proves effective in improving clinical outcomes and patient retention, it may well represent the future of how sleep-disordered breathing is addressed in the modern medical landscape.
